Benefit verification / prior authorization

Application of these coverage criteria depends on the member’s benefit coverage and any applicable Medicare or Medicaid rules; verify member benefits and prior authorization requirements at time of request and follow state/federal specifications in the ‘Applicable State and Federal Regulations’ section.

• Verify member benefit coverage and any plan-specific prior authorization requirements before ordering tests.
• Consult the ‘Applicable State and Federal Regulations’ section for Medicare/Medicaid specifications.

Prior authorization — none specified

The policy excerpts provided do not specify payer prior authorization requirements for TB diagnostic tests. Follow standard clinical evaluation and documentation; check member benefits for any plan-specific PA rules.

• No explicit prior authorization rules are listed in these sections — confirm with payer if needed.
• Document the diagnostic evaluation components when submitting claims.

Prior authorization — none specified in this section

No prior authorization requirements are stated within these policy sections for the tests and procedures described here. Providers should confirm PA needs via the member’s benefit portal or payer communications.

• Policy text does not define PA for specific TB tests in these chunks.
• If in doubt, obtain PA per the member’s plan before testing.

Procedure codes — no PA stated

Procedure and CPT/HCPCS codes listed in the policy are provided as applicable procedure codes; the document does not associate any of these codes with prior authorization requirements.

• Codes are reference tools for billing — they are not shown as requiring PA in the policy.
• Confirm any PA needs with the member’s benefits or payer systems prior to submission.

Prior authorization — no prior authorization requirements stated

No payer prior authorization requirements are described in the provided sections of this policy. Providers should rely on clinical guidance in the document and verify plan-specific rules separately.

• Policy sections reviewed contain no stated PA rules.
• Verify authorization requirements through payer portals as needed.

Test-to-treat expectation for LTBI

Only test for LTBI in individuals who would benefit from treatment; the decision to test presupposes a decision to treat if results are positive.

• Do not perform LTBI testing for screening unless the patient is a candidate for and would receive preventive therapy if positive.
• Document that testing is intended to inform treatment decisions (test-to-treat rationale).

Step therapy — none specified; NAAT recommended when appropriate

The policy describes no step therapy sequencing or formal step-therapy prior authorization requirements for TB diagnostics; WHO guidance recommends NAAT as the initial diagnostic when clinically appropriate but this is not a payer step-therapy rule.

• No plan-level step therapy mandates are described in these sections.
• Follow clinical guidance (e.g., WHO) recommending NAAT (Xpert MTB/RIF or Xpert Ultra) as appropriate for initial diagnosis when indicated.

Step therapy — none specified

No formal step therapy rules are described in the cited policy sections. Providers should follow clinical recommendations and verify benefit rules for specific plans.

• Clinical guidance included in the document does not translate to payer step-therapy requirements.
• Confirm any utilization management rules with the payer.

Screen for LTBI before starting biologic / immunosuppressive therapy

When initiating immunosuppressive or biologic therapies (for example TNFα inhibitors), screen for latent TB infection prior to starting therapy and preferably complete LTBI prophylaxis before initiation; document screening and treatment timing.

• Screen all patients prior to starting TNFα inhibitors or other immunologic therapies.
• Delay immunologic therapy until LTBI prophylaxis is completed when feasible; if treatment must start earlier, document adherence and tolerance of prophylaxis as noted.

Step therapy — none specified (absence note)

These sections do not describe step therapy requirements for TB testing or diagnostics.

• No step therapy requirements are present in the provided chunks.
• Follow clinical guidelines and plan-specific utilization policies as applicable.

Provider documentation and accurate coding required

Providers are responsible for submission of accurate documentation of services performed and appropriate coding according to industry-standard coding guidelines; failure to follow coding/billing rules may result in claim denial or recoupment.

• Code services appropriately per CPT, HCPCS, ICD-10, and other industry standards when submitting claims.
• Maintain accurate clinical documentation to support billed services and medical necessity.

Required evaluation components to document

Documentation of the TB evaluation should include medical history, physical examination, TB infection test results (TST or IGRA), chest radiograph findings, and bacteriologic testing (smear, NAAT, culture, and DST) when evaluating for TB disease.

• Include results of TST or IGRA and an assessment that active TB was excluded prior to LTBI treatment.
• Record chest radiograph findings and bacteriologic test orders/results (smear, NAAT, culture, DST) in the medical record.

Culture submission and drug susceptibility testing documentation

For patients with culture-positive TB, submit one culture isolate from each culture-positive patient to a regional genotyping laboratory and perform/document phenotypic DST for first-line drugs; perform rapid molecular DST on initial isolates and confirm rifampin resistance by sequencing or phenotypic DST when indicated.

• Submit culture isolates for genotyping per guidance.
• Document phenotypic DST for first-line drugs for all TB disease patients and perform confirmatory testing when commercial NAA indicates rifampin resistance.

Specimen submission and rapid NAAT documentation

Request rapid diagnostic NAATs for M. tuberculosis complex on primary specimens when clinical suspicion exists and when results would alter management (for example, HIV, need for rapid species info, or contact tracing); for suspected pulmonary TB, obtain at least two sputum specimens for microscopy and one for rapid molecular testing and send samples for culture and DST as indicated.

• Order NAAT on primary specimens when rapid species or resistance information would change care.
• Collect at least two sputum specimens for microscopy plus one for NAAT in patients able to expectorate; send specimens for liquid culture and culture-based DST in quality-assured labs.

Evidence references (no additional documentation requirements)

This section of the document contains evidence references and does not add additional provider documentation requirements beyond those stated elsewhere in the policy.

• Use referenced guidance and studies to support clinical decisions as needed.
• No new documentation actions are specified in the evidence references section.

Claims denial risk for improper coding/billing

Claims may be denied or recouped if appropriate coding/billing guidelines or current reimbursement policies are not followed; ensure accurate coding and adherence to reimbursement rules when submitting claims.

• Noncompliance with coding and billing guidance (e.g., CCI edits, CMS guidance) can lead to claim denial or recoupment.
• Ensure documentation supports billed services and medical necessity.

Incomplete evaluation may risk inappropriate care or denials

Failure to perform a complete medical evaluation when indicated — including medical history, physical exam, TB infection testing, chest radiograph, and bacteriologic testing — could result in inappropriate management and may affect coverage/authorization.

• Perform and document the five CDC components of TB evaluation when clinically indicated.
• Incomplete evaluation may lead to inappropriate treatment decisions or claims issues.

Exclude active TB before starting LTBI treatment

Before initiating treatment for LTBI, clinicians must exclude active TB using symptom assessment, chest imaging, and bacteriologic testing as indicated; testing that does not exclude active TB prior to LTBI treatment may be inappropriate.

• Assess for symptoms suggestive of TB, obtain chest radiograph, and sample for microbiology if radiographic signs of active TB are present.
• Document explicit exclusion of active TB in the medical record before starting LTBI therapy.

Government policy precedence — check LCDs/NCDs/state rules

If this policy conflicts with any applicable government policy (e.g., LCDs, NCDs, or state Medicaid), the government policy takes precedence; follow government requirements to avoid denials.

• Check for applicable Medicare/Medicaid coverage rules and local coverage determinations when they differ from this policy.
• Adhere to government policy where conflicts exist to guide coverage decisions.

Authorization/denial criteria not specified in these sections

No explicit authorization or denial criteria are presented in the provided document sections.

• Policy sections reviewed do not define specific authorization or denial rules beyond general statements.
• For authorization decisions, verify plan-specific criteria and consult payer resources as needed.